(IMG SOURCE: www.aivivo.co)
We are delighted to announce that o2h ventures backed AI VIVO have won “the Best Innovation in Pharma” at the Cogx 2020 Awards. The other shortlisted companies in this category included HealX and BenevolentAI.
The CogX Awards are an exciting celebration of innovation and transformational opportunities in the world – a platform to celebrate the companies and individuals making a difference.
The 2020 award categories were spread across five themes: Recognising Leadership, Best AI Product, Best Innovation & Product, Outstanding Achievements & Research Contributions, and Global Goals – with more than 60 individual categories covering verticals from AI to Global Leadership, Financial Services to Climate Change, and from GenZ to Covid-19 Response.
AI VIVO is a Cambridge based systems pharmacology company which specialises in a powerful phenotypic approach to drug discovery that still works when little is known about disease specific targets.
Earlier this year, AI VIVO developed an AI driven phenotypic model for COVID-19. The company then used its prediction engine to rank candidate drugs that can be used for COVID-1-9 treatment. Interestingly, more than 50 compounds from their top ranked list are now in clinical trials for COVID-19 and several of them have showed positive outcomes (including Dexamethasone and Baracitinib). The company’s prediction engine is also optimised for drug combination prediction which could increase synergistic effect.
o2h ventures invested into AI VIVO from its human health EIS fund. The Fund invests in S/EIS seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies.